- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
- Next-week expectancy is positive at 57.14% based on similar historical setup states.
COAG
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Hemab Therapeutics Holdings, Inc. Common Stock · Healthcare · Biotechnology
Latest close
47.31 USD
-4.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is - below the Trend Line and sits at 83.4% of its 52-week range. The latest completed week returned -4.0%, after a 46.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: earnings are due in 15d.
Setup score
47
out of 100
Latest Close
47.31 USD
24 Jul 2026
1W Return
-4.0%
latest completed week
4W Return
46.2%
short-term follow-through
12W Return
39.1%
quarterly tape
Trend Breadth
0.0%
0 of 13 weeks active
Volume Ratio
1.5x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- 7 reversal markers appear in the recent smart-money tape.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-4.0%
Latest completed week; four-week move 46.2%.
Indicator stack
0/50
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 57.14%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
52/100
46 relevant articles in the latest sentiment read.
Event risk
15d
Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is - below the Trend Line and sits at 83.4% of its 52-week range. The latest completed week returned -4.0%, after a 46.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2312-week average 0.20
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.23Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers77 reversal markers
No recent accumulation markers. 7 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 46.2% over four weeks, 39.1% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 42%
Model confidence 41%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength58/100Blend of value, momentum, and quality. Underlying universe rank 43; rank 1 is best.
Value53/100Relative valuation strength. Underlying universe rank 48; rank 1 is best.
Quality51/100Profitability and accounting quality. Underlying universe rank 50; rank 1 is best.
Momentum53/100Medium-term price momentum. Underlying universe rank 48; rank 1 is best.
Growth53/100Revenue and earnings growth. Underlying universe rank 48; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -3.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -7.5% Net share repurchases relative to market value.
- Shareholder yield
- -7.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.7x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 46 relevant articles.
8 positive · 35 neutral · 3 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings15dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-9.3%Distance below the 52-week high.
13-week volatility15.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
1 May
29 May
26 Jun
24 Jul
Weeks higher6 of 126 weeks finished lower.
Best week+29.6%Week of 17 Jul.
Worst week-26.1%Week of 8 May.
Latest week-4.0%Week of 24 Jul.
Shape of recent returns
Strong gains6
Modest gains0
Flat weeks0
Modest losses1
Sharp losses5
Recent vol15.1%13-week weekly-return volatility.
Base vol15.1%52-week weekly-return volatility.
Up/down split6/6Count of positive and negative weeks in the 52-week window.
Average skew17.0% / -9.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape37/100
Trend, activity pressure, participation, and risk combine to a 37/100 tape read.
Indicator analysis4/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.23; 7 reversal markers Next-Week ExpectancyPositive 57.14%Next-week expectancy is positive with a 57.14% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors53/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 85; Small Cap Core rank 52 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 46 relevant articles.
Hemab Therapeutics Holdings Ord Shs (Proposed) (COAG) Institutional Confidence Insiders50/100No recent insider transaction evidence is stored.
Earnings15dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 47.31 USD | -4.0% | - | 32.24 USD | 0.00 | - | 2.5M | Off |
| 17 Jul 2026 | 49.29 USD | 29.6% | - | 30.98 USD | 0.00 | - | 1.7M | Off |
| 10 Jul 2026 | 38.03 USD | 22.7% | - | 29.32 USD | 0.00 | - | 1.7M | Off |
| 3 Jul 2026 | 31.00 USD | -4.2% | - | 28.45 USD | 0.00 | - | 1.2M | Off |
| 26 Jun 2026 | 32.37 USD | 10.7% | - | 28.16 USD | 0.00 | - | 1.3M | Off |
| 19 Jun 2026 | 29.24 USD | 17.1% | - | 27.64 USD | 0.00 | - | 2.5M | Off |
| 12 Jun 2026 | 24.98 USD | -1.3% | - | 27.41 USD | 0.00 | - | 975.5K | Off |
| 5 Jun 2026 | 25.30 USD | -11.2% | - | 27.81 USD | 0.00 | - | 824.5K | Off |
| 29 May 2026 | 28.50 USD | 10.1% | - | 28.32 USD | 0.00 | - | 675.7K | Off |
| 22 May 2026 | 25.89 USD | -7.8% | - | 28.27 USD | 0.00 | - | 774.5K | Off |
| 15 May 2026 | 28.07 USD | 11.7% | - | 29.06 USD | - | - | 868.0K | Off |
| 8 May 2026 | 25.12 USD | -26.1% | - | 29.56 USD | - | - | 2.0M | Off |
| 1 May 2026 | 34.00 USD | - | - | 34.00 USD | - | - | 4.1M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.